上呼吸道益生菌Biohalo23用于呼吸道感染及中耳炎的专家共识——现有循证科学依据及未来研究建议  

Expert Consensus on the Use of Upper Respiratory Tract Probiotic Biohalo23 in Respiratory Tract Infection and Otitis Media:Available Evidence-Based Scientific Evidence and Recommendations for Future Research

作　　者：王强[1] 张亚同[2] 成晓玲[3] 郭智 刘洋 夏立红[6] 刘志刚[7] 郑俊青[7] 张子和 孙凯 沈关心[10] WANG Qiang;ZHANG Ya-tong;CHENG Xiao-ling;GUO Zhi;LIU Yang;XIA Li-hong;LIU Zhi-gang;ZHENG Jun-qing;ZHANG Zi-he;SUN Kai;SHEN Guan-xin(College of Medicine,Wuhan University of Science and Technology,Wuhan 430065,China;Beijing Hospital,Beijing 100730,China;Beijing Children's Hospital,Capital Medical University,Beijing 100045,China;Huazhong University of Science and Technology Union Shenzhen Hospital,Shenzhen 518052,China;Wuhan Asian General Hospital,Wuhan 430056,China;Affiliated Hospital of Shandong University of Traditional Chinese Medicine,Jinan 250014,China;Jinan Maternity and Child Care Hospital,Jinan 250001,China;Shandong Maternity and Child Care Hospital,Jinan 250000,China;First Affiliated Hospital of Shandong First Medical University,Jinan 250014,China;Tongji Medical College Huazhong University of Science and Technology,Wuhan 430030,China)

机构地区：[1]武汉科技大学医学院,武汉430065 [2]北京医院,北京100730 [3]首都医科大学附属北京儿童医院,北京100045 [4]华中科技大学协和深圳医院,深圳518052 [5]武汉亚心总医院,武汉430056 [6]山东中医药大学附属医院,济南250014 [7]济南市妇幼保健院,济南250001 [8]山东省妇幼保健院,济南250000 [9]山东第一医科大学第一附属医院,济南250014 [10]华中科技大学同济医学院,武汉430030

出　　处：《中国合理用药探索》2024年第8期33-47,共15页Chinese Journal of Rational Drug Use

摘　　要：呼吸道菌群决定着宿主是否成为呼吸道感染易感体质,并与宿主免疫系统共筑成人体对抗感染的第一道防线。呼吸道菌群特征的塑造与生命早期的无症状病毒暴露、生命早期呼吸道感染、过敏体质以及孕期或生命早期的抗生素暴露息息相关,这些因素也是日后形成反复呼吸道感染或过敏体质的重要因子。近年来,有许多研究试图探索人体微生态干预对调节宿主免疫及预防呼吸道感染的效果,但由于研究之间存在非同质化且不一致的再现性,使医生对于推荐益生菌给患者持有不同的见解。益生菌成品研究作为近几年学术界推荐的科研循证方法,是推动益生菌产业良性发展的有效方法,研究结论更符合真实世界使用结果,利于医生临床使用和消费者选择参考。鉴于中国和欧洲真实世界中的上呼吸道益生菌Biohalo23临床实践经验与患者的积极正向反馈,本专家组认为,具有循证科学依据并在多项研究中取得一致及积极临床研究结果的上呼吸道益生菌Biohalo23,可被视为医生在标准药物治疗基础上推荐给需要的患者以提高呼吸道感染相关生活质量并减轻呼吸道感染易感负担的“工具”,同时也鼓励医生关注呼吸道微生态在医学应用发展的新研究领域,以及呼吸道菌群干预可提供更佳疾病管理的巨大潜力。The respiratory tract microbiota determines whether the host has predisposition for respiratory tract infection,and builds up the first line of defence against infection together with the host immune system.The characterization of respiratory flora are closely related to early-life asymptomatic viral exposure,early-life respiratory infection,allergic constitution,and antibiotic exposure during pregnancy or early life,constituting important factors underlying future recurrent respiratory infection or allergic constitution.In recent years,many attempts through studies have been tried to explore the effects of human microbiome-based interventions on the regulation of host immunity and the prevention of respiratory tract infections.However,the heterogeneous and inconsistent reproducibility between studies resulted in inconsistent opinions among physicians in terms of the recommendation of probiotics to patients.As an evidence-based research method recommended by academia in recent years,probiotic finished product research is an effective method to promote the benign development of probiotics industry.The research results are more consistent with the administration outcomes in a real-world setting and hence conducive to experts'clinical use and also serving as reference for consumer when making choice.On the ground of applying upper respiratory tract probiotic Biohalo23 in clinical practice in China and Europe and relevant positive feedback from patients,the expert panel supposes that the upper respiratory tract probiotic Biohalo23,with evidence-based scientific evidence and consistent and positive clinical research results across multiple studies,can be considered as a"tool"for physicians to recommend to patients in need on the basis of standard drug therapy to improve quality of life associated with respiratory tract infection and reduce the burden of predisposition for respiratory tract infection,and the panel also encourages physicians to devote attention to new research areas of the development and medical applic

关 键 词：上呼吸道益生菌Biohalo23 呼吸道感染 中耳炎 专家共识 循证科学依据 

分 类 号：R714.253[医药卫生—妇产科学]